)
05:30 AM IST
Mylan NV
Shares of the company, which on Tuesday also disclosed a warning letter it received from the FDA earlier this month, fell nearly 2 percent to $33.91 after the bell.
The news comes a day after the European Union authorities stepped in to effectively ban sales of valsartan made by an India-based Mylan unit after some batches were found to contain the same impurity, N-nitrosodiethylamine (NDEA).
Mylan said on Tuesday it would recall at least 15 lots of medicines containing valsartan distributed in the United States between March 2017 and November 2018 and manufactured by units Mylan Pharmaceuticals and Mylan Laboratories.
Over the past year, global health authorities have been cracking down on valsartan and drugs containing the substance as an active ingredient after several batches were found to contain NDEA and a second possible carcinogen, N-nitrosodimethylamine (NDMA).
The U.S. FDA last month halted imports of drug ingredients or medicines containing ingredients produced at a factory belonging to a Chinese bulk manufacturer of valsartan, Zhejiang Huahai Pharmaceuticals .
Huahai had recalled the tainted product from consumers in the United States in July.
(This article has not been edited by Zeebiz editorial team and is auto-generated from an agency feed.)
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.
RECOMMENDED STORIES
)
)
)
)
)
)
)
)
India will soon be world's third-largest economy: PM Modi
Household savings in India drop to 18.1% of GDP in FY24: CareEdge Ratings
Cost of home-cooked thalis declines 6% in May, driven by cheaper vegetables: Crisil report
India GDP growth at one-year high of 7.4% in Q4, FY25 expansion at 6.5% 
India set to become 3rd largest economy by 2027: Piyush Goyal
